Mexiprim, pills 125mg 30pcs

Composition

1 tablet contains: Active ingredient-ethylmethylhydroxypyridine succinate in terms of 100% substance-0.125 g. Excipients (tablet core): Kaolin — 0.00247 g, Sodium Carboxymethyl starch-0.01258 g, Microcrystalline cellulose-0.1135 g, Povidone-0.0134 g, Talc — 0.0053 g, Calcium stearate — 0.00275 g. Excipients (shell): Hypromellose — 0.00495 g, Macrogol-0.00128 g, Titanium dioxide-0.00165 g, Talc-0.00037 g

Pharmacological action

Mexiprim is a heteroaromatic antioxidant. It has a wide range of pharmacological activity: increases the body’s resistance to stress, shows an anxiolytic effect that is not accompanied by a muscle relaxant effect; has nootropic properties, prevents and reduces learning and memory disorders that occur during aging and exposure to various pathogenic factors; has an anticonvulsant effect; shows antioxidant and antihypoxic properties; increases concentration and performance; weakens the toxic effect of alcohol. The drug improves the metabolism of brain tissues and their blood supply, improves microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membrane structures of blood cells (red blood cells and platelets). It has a hypolipidemic effect, reduces the content of total cholesterol and low-density lipoproteins. The mechanism of action of Mexiprim is due to its antioxidant and membrane-protective action. It inhibits lipid peroxidation, increases the activity of superoxide oxidase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, transport neurotransmitters, and improve synaptic transmission. Mexiprim increases the level of dopamine in the brain. It causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of ATP and creatine phosphate, activation of energy-synthesizing functions of mitochondria, and stabilization of cell membranes.

Indications

• anxiety disorders in neurotic and neurosis-like States;
• vegetative-vascular dystonia;
• mild cognitive disorders of different Genesis (with psychoorganic syndrome and asthenic disorders caused by acute and chronic cerebrovascular disorders, traumatic brain injuries, neuroinfections and intoxications, senile and atrophic processes);
• memory disorders and intellectual insufficiency in the elderly;
• the impact of extreme (stress) factors;
• alcohol withdrawal syndrome with prevalence of neurosis and vegetative-vascular disorders.

Use during pregnancy and lactation

Currently, the possibility and safety of using Mexiprim during pregnancy and lactation are insufficiently studied, so the use of the drug in this category of patients is contraindicated.

Contraindications

• Increased individual sensitivity to Mexiprim;
• acute liver and kidney function disorders;
• childhood;
• pregnancy;
• breast-feeding.

Side effects

Individual adverse reactions may occur:  nausea and dryness of the oral mucosa, drowsiness, allergic reactions.

Interaction

Compatible with psychotropic drugs.

Increases the effect of benzodiazepine anxiolytics, anticonvulsants (carbamazepine), antiparkinsonian agents (levodopa), reduces the toxic effect of ethyl alcohol

How to take, course of use and dosage

Mexiprim is prescribed orally.

The therapeutic doses used and the duration of treatment are determined by the sensitivity of patients to the drug.

Start treatment with a dose of 0.25-0.5 g; the average daily dose is 0.25-0.5 g, the maximum daily dose is 0.8 g. The daily dose of the drug is distributed in 2-3 doses during the day.

For the treatment of patients with anxiety disorders, vegetative-vascular dysfunctions and cognitive disorders, Mexiprim is used for 2-6 weeks.

When stopping alcohol withdrawal syndrome, Mexiprim is used for 5-7 days.

Course therapy with Mexiprim is completed gradually, reducing the dose of the drug within 2-3 days.

Overdose

Symptoms: sleep disorders (insomnia, in some cases — drowsiness).

Treatment: as a rule, it is not required — the symptoms disappear on their own within a day. In severe cases of insomnia, it is recommended to take nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg.

Description

Tablets are round, biconvex, film-coated, white to white with a creamy tint of color, on the break-from white to white with a grayish, or yellowish, or creamy tint of color.

Complete set

Film-coated tablets of 125 mg each. 10 tablets in a contour cell package made of polyvinyl chloride film and aluminum foil. 1,2,3,4 or 6 contour cell packages together with the instructions for use are placed in a cardboard box.

Special instructions

The degree of restrictions is determined by the individual tolerance of the drug. During the treatment period, care should be taken when driving vehicles and engaging in other potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Form of production

Film-coated tablets of 125 mg each. 10 tablets in a contour cell package made of polyvinyl chloride film and aluminum foil. 1,2,3,4 or 6 contour cell packages together with the instructions for use are placed in a cardboard box.

Storage conditions

Store in a dry place, protected from light and out of reach of children, at a temperature not exceeding 30° C.

Shelf

life is 5 years. Do not use after the expiration date indicated on the package.

Active ingredient

Ethylmethylhydroxypyridine Succinate

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Concussion and other traumatic brain injuries, Circulatory disorders, Hangover, Vegetative-vascular disorders, Angina Pectoris, Myocardial infarction, Exposure to adverse factors, Atherosclerosis, Asthenia